ArticleNoro psikiyatri arsivi2017
Metabolic Effects of Antidepressant Treatment.
Article in Noro psikiyatri arsivi, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- The effect of bright light therapy on glycemic control and cortisol rhythmicity in depression: a randomized controlled trial.Frontiers in psychiatry · 2026Trial
- Is MASLD Not Just a Liver Disease? Bidirectional Gut-Liver Crosstalk as a Driver of Chronic Liver Disease.Life (Basel, Switzerland) · 2026Review
- Review
- Article
- Fluoxetine promotes IL-10-dependent metabolic defenses to protect from sepsis-induced lethality.Science advances · 2025Article
- Article
- What could be the reasons for not losing weight even after following a weight loss program?Journal of health, population, and nutrition · 2024Review
- Lipids in Psychiatric Disorders: Functional and Potential Diagnostic Role as Blood Biomarkers.Metabolites · 2024Review
- Article
- Fluoxetine promotes immunometabolic defenses to mediate host-pathogen cooperation during sepsis.bioRxiv : the preprint server for biology · 2023Article
- The Potential Use of Monocyte-to-High-Density Lipoprotein Ratio as a Chronic Inflammatory Marker in Major Depressive Disorder.Psychiatry and clinical psychopharmacology · 2023Article
- Brain deficit patterns of metabolic illnesses overlap with those for major depressive disorder: A new metric of brain metabolic disease.Human brain mapping · 2023Article
- Comparative metabolomic analysis in plasma and cerebrospinal fluid of humans and in plasma and brain of mice following antidepressant-dose ketamine administration.Translational psychiatry · 2022Article
- Lipid Biomarkers in Depression: Does Antidepressant Therapy Have an Impact?Healthcare (Basel, Switzerland) · 2022Article
- Article
- Therapy Management of Metabolic Disorder Comorbidity With Depression.Frontiers in psychology · 2021Review
- Severe Depressive Episode with Psychotic Symptoms and Type 2 Diabetes: A 2010-2017 Longitudinal Study.Medical science monitor : international medical journal of experimental and clinical research · 2019Article
- Fluoxetine induces lipid metabolism abnormalities by acting on the liver in patients and mice with depression.Acta pharmacologica Sinica · 2018Article
- Adrenal activity and metabolic risk during randomized escitalopram or placebo treatment in PCOS.Endocrine connections · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis study aimed to investigate body measurements, glucose-insulin metabolism, and lipid profile in patients with anxiety and depressive symptoms and also the effects of antidepressant drugs on these metabolic parameters.
methodsThe study included 40 outpatients and 32 healthy controls. The patients received antidepressant treatment (sertraline, escitalopram, fluoxetine, and venlafaxine) for 8 weeks. Body measurements were performed, and lipid, fasting blood glucose, and insulin levels were measured before and after treatment in patients and once in healthy controls. Insulin resistance was evaluated using the homeostasis model assessment (HOMA) index.
resultsBody mass index was higher in patients than in healthy controls, and there was no change in patients after treatment. In patients, high-density lipoprotein (HDL) cholesterol levels increased owing to the antidepressant treatment. Insulin level and HOMA index had a tendency to decrease with the treatment in patients and were similar to those of healthy controls before the treatment; however, they became lower than those of healthy controls after the treatment. There was an increase in waist circumference and total and HDL cholesterol levels, whereas there was a decrease in fasting blood glucose levels with treatment in patients using escitalopram. There was no change in body measurements and biochemical and hormone values in patients using fluoxetine, sertraline, and venlafaxine. There was an increase in weight, body mass index, and waist circumference after treatment in patients with depression; however, there was no change in patients with anxiety.
conclusionIn patients with psychiatric disorders having anxiety and depressive symptoms, metabolic changes independent of drugs and the metabolic effects of drugs are present.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.